Sujing Zhuang1, Baogui Liu2, Shifeng Guo1, Yanzhong Xue1, Lin Wu3, Shiqi Liu4, Chunling Zhang3, Xiuyan Ni5. 1. Department of Neurology, Linyi Central Hospital, Linyi, 276400, Shandong, China. 2. Department of Anesthesiology, Linyi Central Hospital, Linyi, 276400, Shandong, China. 3. Department of Intensive Care Unit 2, Affiliated Hospital of Jining Medical University, Jining, 272000, Shandong, China. 4. Department of Gastrointestinal Surgery, Affiliated Hospital of Jining Medical University, Jining, 272000, Shandong, China. 5. Department of Radiotherapy, Linyi Central Hospital, Linyi, 276400, Shandong, China. mgpjfnuxiemu8211@163.com.
Abstract
BACKGROUND: Germacrone (GM) is a terpenoid compound which is reported to have anti-inflammatory and anti-oxidative effects. However, its role in treating traumatic brain injury (TBI) remains largely unknown. METHODS: Male C57BL/6 mice were divided into the following groups: control group, TBI group [controlled cortical impact (CCI) model], CCI + 5 mg/kg GM group, CCI + 10 mg/kg GM group and CCI + 20 mg/kg GM group. GM was administered via intraperitoneal injection. The neurological functions (including motor coordination, spatial learning and memory abilities) and brain edema were measured. Nissl staining was used to detect the neuronal apoptosis. Colorimetric assays and enzyme linked immunosorbent assay (ELISA) kits were used to determine the expression levels of oxidative stress markers including myeloperoxidase (MPO), malondialdehyde (MDA) and superoxide dismutase (SOD), as well as the expressions of inflammatory markers, including tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6). Additionally, protein levels of Nrf2 and p-p65 were detected by Western blot assay. RESULTS: GM significantly ameliorated motor dysfunction, spatial learning and memory deficits of the mice induced by TBI and it also reduced neuronal apoptosis and microglial activation in a dose-dependent manner. Besides, GM treatment reduced neuroinflammation and oxidative stress compared to those in the CCI group in a dose-dependent manner. Furthermore, GM up-regulated the expression of antioxidant protein Nrf2 and inhibited the expression of inflammatory response protein p-p65. CONCLUSIONS: GM is a promising drug to improve the functional recovery after TBI via repressing neuroinflammation and oxidative stress.
BACKGROUND:Germacrone (GM) is a terpenoid compound which is reported to have anti-inflammatory and anti-oxidative effects. However, its role in treating traumatic brain injury (TBI) remains largely unknown. METHODS: Male C57BL/6 mice were divided into the following groups: control group, TBI group [controlled cortical impact (CCI) model], CCI + 5 mg/kg GM group, CCI + 10 mg/kg GM group and CCI + 20 mg/kg GM group. GM was administered via intraperitoneal injection. The neurological functions (including motor coordination, spatial learning and memory abilities) and brain edema were measured. Nissl staining was used to detect the neuronal apoptosis. Colorimetric assays and enzyme linked immunosorbent assay (ELISA) kits were used to determine the expression levels of oxidative stress markers including myeloperoxidase (MPO), malondialdehyde (MDA) and superoxide dismutase (SOD), as well as the expressions of inflammatory markers, including tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6). Additionally, protein levels of Nrf2 and p-p65 were detected by Western blot assay. RESULTS:GM significantly ameliorated motor dysfunction, spatial learning and memory deficits of the mice induced by TBI and it also reduced neuronal apoptosis and microglial activation in a dose-dependent manner. Besides, GM treatment reduced neuroinflammation and oxidative stress compared to those in the CCI group in a dose-dependent manner. Furthermore, GM up-regulated the expression of antioxidant protein Nrf2 and inhibited the expression of inflammatory response protein p-p65. CONCLUSIONS:GM is a promising drug to improve the functional recovery after TBI via repressing neuroinflammation and oxidative stress.
Authors: Ralf Gold; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Gavin Giovannoni; Krzysztof Selmaj; Carlo Tornatore; Marianne T Sweetser; Minhua Yang; Sarah I Sheikh; Katherine T Dawson Journal: N Engl J Med Date: 2012-09-20 Impact factor: 91.245
Authors: Eitan Okun; Kathleen Griffioen; Boaz Barak; Nicholas J Roberts; Kamilah Castro; Mario A Pita; Aiwu Cheng; Mohamed R Mughal; Ruiqian Wan; Uri Ashery; Mark P Mattson Journal: Proc Natl Acad Sci U S A Date: 2010-08-16 Impact factor: 11.205
Authors: Diego Lozano; Gabriel S Gonzales-Portillo; Sandra Acosta; Ike de la Pena; Naoki Tajiri; Yuji Kaneko; Cesar V Borlongan Journal: Neuropsychiatr Dis Treat Date: 2015-01-08 Impact factor: 2.570
Authors: Quante Singleton; Kumar Vaibhav; Molly Braun; Chandani Patel; Andrew Khayrullin; Bharati Mendhe; Byung R Lee; Ravindra Kolhe; Helen Kaiser; Mohamed E Awad; Tunde Fariyike; Ranya Elsayed; Mohammed Elsalanty; Carlos M Isales; Yutao Liu; Mark W Hamrick; Krishnan M Dhandapani; Sadanand Fulzele Journal: Cells Date: 2019-01-17 Impact factor: 6.600